• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Pregnancy and Postpartum Course
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Pregnancy and Postpartum Course
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » psychopharmacology

Articles Tagged with ''psychopharmacology''

survey.jpeg

Psychopharm Commandment 3: Lithium Toxicity

October 10, 2022
Chris Aiken, MD and Kellie Newsome, PMHNP

Lithium toxicity: How to avoid it, and what to do when it happens.


Read More
CLINICAL UPDATE

Six Tips From Prescribing Psychotropics

August 1, 2022
Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Chris Aiken, MD. 

Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.


Read More

What Gets in the Way of Antidepressants?

August 1, 2022
Chris Aiken, MD and Garrett Rossi, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Garrett Rossi, MD.
Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Chris Aiken, MD.
Editor-in-Chief, The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Rossi and Dr. Aiken, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Recent research has added to our understanding of factors that inhibit response to treatment, including major stress, nonadherence, and anxiety.


Read More
Quetiapine_sm.png

Quetiapine Reconsidered

June 1, 2022
Paul Riordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University. Dr. Riordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It is the best of drugs; it is the worst of drugs. Quetiapine (Seroquel) has a few benefits that are unmatched by other medications, and here we explore where it fits in depression, bipolar, schizophrenia, as well as off-label uses like anxiety and sleep.


Read More

Real-World Alcohol Use Disorder Treatment

March 1, 2022
Ismene Petrakis, MD
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Ismene Petrakis, MDIsmene Petrakis, MD

Addiction psychiatrist and professor at Yale School of Medicine. Chief of Mental Health, VA Connecticut Healthcare System, New Haven, CT.

Dr. Petrakis has disclosed that she participated in a study in which she did not receive any compensation from Alkermes apart from medication and Alkermes did not fund the study. Dr. Capurso has reviewed this material and found no evidence of bias pertaining to this educational activity.

Many patient with alcohol use disorder (AUD) also have comorbid psychiatric illness. Treating these patients can be challenging however there are evidenced based approaches that have been shown to be effective. Dr. Petrakis reviews the latest evidence in treating AUD in this challenging population.
Read More

Medications for Alcohol Use Disorder: An Overview

March 1, 2022
Mikveh Warshaw, NP.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Mikveh Warshaw, NP. Psychiatric mental health nurse practitioner, Community Health Center Inc. and faculty member of Center for Key Populations (CKP) Program, Middletown, CT. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
There are three FDA approved medications for alcohol use disorder (AUD) and many others that have been tested. Here, we summarize the evidence behind the various medications for alcohol use disorder and highlight clinical scenarios in which each should be considered.
Read More

Meds for Alcohol Use Disorders

January 18, 2022
Mikveh Warshaw, NP.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Mikveh Warshaw, NP. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Naltrexone has shown efficacy for the treatment of alcohol use disorder in tightly controlled trials. Here, researchers demonstrate the efficacy of naltrexone in a large scale naturalistic study.
Read More

How to Treat ADHD in Bipolar Disorder

November 5, 2021
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD.
Read More

Brexpiprazole Ineffective in Mania

September 28, 2021
Richard Moldawsky, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Choosing an antipsychotic in bipolar disorder just got more complicated. This series of industry-sponsored trials reveals that their anti-manic activity may not be a class effect.
Read More

Intranasal Esketamine: New Hope for Suicidal Patients?

April 12, 2021
Daniel Carlat, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Victoria Hendrick, MDVictoria Hendrick, MD.

Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.    

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report. Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Imagine a drug that resolves depression within hours in people at imminent risk of suicide. Esketamine may be such a drug — but is it a miracle cure? Here we look at the data and discuss the pros and cons of this new treatment.
Read More
Previous 1 2 3 4 5 6 7 8 9 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.